share_log

Avalo Therapeutics | 8-K: Current report

Avalo Therapeutics | 8-K: Current report

Avalo Therapeutics | 8-K:重大事件
美股sec公告 ·  06/24 16:07
Moomoo AI 已提取核心信息
Avalo Therapeutics, Inc. announced on June 24, 2024, the appointment of Paul Varki as the company's new Chief Legal Officer. Varki, aged 52, brings over two decades of legal experience in the pharmaceutical industry to Avalo Therapeutics. His previous roles include General Counsel at Idorsia Pharmaceuticals US Inc., Vice President of Legal at Amarin Corporation plc, and senior legal positions at Braeburn Pharmaceuticals and Egalet Pharmaceuticals. Varki's extensive background also includes various legal roles at GlaxoSmithKline and practice in FDA regulatory law. His academic credentials include a J.D. from Temple University School of Law, a Master of Public Health from George Washington University, and a Bachelor of Arts from the College of William and Mary. Alongside his appointment, Varki entered into an employment agreement with Avalo Therapeutics, which includes a base salary, potential bonuses, and equity incentives. The agreement also outlines severance benefits and restrictive covenants. Avalo Therapeutics is a clinical-stage biotechnology company focusing on immune dysregulation treatments, with AVTX-009 as its lead asset targeting inflammatory diseases.
Avalo Therapeutics, Inc. announced on June 24, 2024, the appointment of Paul Varki as the company's new Chief Legal Officer. Varki, aged 52, brings over two decades of legal experience in the pharmaceutical industry to Avalo Therapeutics. His previous roles include General Counsel at Idorsia Pharmaceuticals US Inc., Vice President of Legal at Amarin Corporation plc, and senior legal positions at Braeburn Pharmaceuticals and Egalet Pharmaceuticals. Varki's extensive background also includes various legal roles at GlaxoSmithKline and practice in FDA regulatory law. His academic credentials include a J.D. from Temple University School of Law, a Master of Public Health from George Washington University, and a Bachelor of Arts from the College of William and Mary. Alongside his appointment, Varki entered into an employment agreement with Avalo Therapeutics, which includes a base salary, potential bonuses, and equity incentives. The agreement also outlines severance benefits and restrictive covenants. Avalo Therapeutics is a clinical-stage biotechnology company focusing on immune dysregulation treatments, with AVTX-009 as its lead asset targeting inflammatory diseases.
Avalo Therapeutics宣布于2024年6月24日任命Paul Varki为该公司的新首席法务官。 52岁的Varki在药品行业拥有20多年的法律经验,此次他担任Avalo Therapeutics的法律总顾问一职。他以前的职位包括Idorsia Pharmaceuticals US Inc的总法律顾问,Amarin Corporation plc的法务副总裁以及Braeburn Pharmaceuticals和Egalet Pharmaceuticals的高级法律职位。Varki的广泛背景还包括在GlaxoSmithKline担任各种法律角色以及在FDA监管法方面的实践。他的学术...展开全部
Avalo Therapeutics宣布于2024年6月24日任命Paul Varki为该公司的新首席法务官。 52岁的Varki在药品行业拥有20多年的法律经验,此次他担任Avalo Therapeutics的法律总顾问一职。他以前的职位包括Idorsia Pharmaceuticals US Inc的总法律顾问,Amarin Corporation plc的法务副总裁以及Braeburn Pharmaceuticals和Egalet Pharmaceuticals的高级法律职位。Varki的广泛背景还包括在GlaxoSmithKline担任各种法律角色以及在FDA监管法方面的实践。他的学术资历包括来自天普大学法学院的J.D.学位,来自乔治华盛顿大学的公共卫生硕士学位以及来自威廉和玛丽学院的文学学士学位。与他的任命一起,Varki与Avalo Therapeutics签订了就业协议,其中包括基本薪水,可能的奖金和股权激励措施。协议还概述了解雇福利和限制性契约。Avalo Therapeutics是一家专注于治疗免疫失调的生物技术临床阶段公司,其主要产品AVTX-009的目标是炎症性疾病。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息